EURONEXT-PAR$VALN
Valneva SE · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Headline financials
Revenue & EPS history
Valneva · Revenue · Quarterly
€41.4M
Q3 2023-73.8%vs Q3 2022
Revenue by segment
Valneva · €120M total across 4 segments · Q3 2025
- IXIARO/JESPECT (Japanese encephalitis)€74.3M—62.2%
- DUKORAL€21.5M—18.0%
- Third-party distribution€16.1M—13.5%
- IXCHIQ€7.6M—6.4%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q3 2023
+1.5%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+0.5%
Avg return
30 days after
44%
7 / 16 earnings
Positive
+40.7%
Q1 2023
Best reaction
-16.1%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.2% | -3.3% | -10.0% | |
| Q3 2025 | +0.4% | +0.5% | -7.2% | |
| H1 2025 | +29.2% | +35.6% | +8.0% | |
| Q1 2025 | +4.0% | -0.4% | -4.9% | |
| Q1 2024 | -5.0% | -1.1% | +11.7% | |
| Q4 2023 | -10.6% | -1.5% | -4.3% | |
| Q3 2023 | +5.3% | +2.6% | -13.5% | |
| Q2 2023 | -4.8% | -8.0% | -19.1% | |
| Q1 2023 | +40.7% | +28.9% | +33.6% | |
| Q4 2022 | -4.5% | -10.3% | -3.1% | |
| Q3 2022 | +5.4% | +9.4% | +5.7% | |
| Q2 2022 | -0.5% | -2.3% | -19.5% | |
| Q1 2022 | +2.1% | -3.0% | -7.9% | |
| Q4 2021 | -8.7% | -7.6% | -13.6% | |
| Q2 2021 | -16.1% | -11.2% | +63.3% | |
| Q1 2021 | -7.1% | -15.7% | -10.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro